{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T23:50:22Z","timestamp":1658706622715},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.encep.2012.01.014","type":"journal-article","created":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T20:30:19Z","timestamp":1387830619000},"page":"188-196","source":"Crossref","is-referenced-by-count":4,"title":["Efficacit\u00e9 des traitements pharmacologiques dans les troubles envahissants du d\u00e9veloppement\u00a0: une revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"40","author":[{"given":"L.","family":"B\u00e9h\u00e9rec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Quilici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rosier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gerardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Campion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Guillin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1542\/peds.2007-0984","article-title":"Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders","volume":"121","author":"Mandell","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.encep.2012.01.014_bib0010","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.encep.2008.04.008","article-title":"Les traitements psychotropes prescrits dans un \u00e9tablissement public de sant\u00e9 mentale accueillant des personnes atteintes d\u2019autisme et des polyhandicap\u00e9s","volume":"35","author":"Armand-Banger","year":"2009","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2012.01.014_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0013-7006(05)82394-2","article-title":"Etude descriptive de l\u2019utilisation de psychotropes chez les personnes autistes de 20\u00a0\u00e0 35ans en institution du Languedoc-Roussillon","volume":"31","author":"Baghdali","year":"2005","journal-title":"Enc\u00e9phale"},{"issue":"10","key":"10.1016\/j.encep.2012.01.014_bib0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.encep.2012.01.014_bib0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0320","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.encep.2012.01.014_bib0325","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.encep.2012.01.014_bib0045","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","article-title":"A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder","volume":"53","author":"McDougle","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0050","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.encep.2012.01.014_bib0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.encep.2012.01.014_bib0060","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0065","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.encep.2012.01.014_bib0070","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: an open pilot study","volume":"40","author":"Malone","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v62n0612h","article-title":"Clozapine in the treatment of aggression in an adolescent with autistic disorder","volume":"62","author":"Chen","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2012.01.014_bib0085","first-page":"340","article-title":"Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour","volume":"26","author":"Gobbi","year":"2001","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"10.1016\/j.encep.2012.01.014_bib0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2009.0057","article-title":"Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder","volume":"20","author":"Lambrey","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0095","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/ajp.153.5.738a","article-title":"Clinical effects of clozapine on autistic disorder","volume":"153","author":"Zuddas","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/JCP.0b013e318218f4a1","article-title":"Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors","volume":"31","author":"Beherec","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"9701","key":"10.1016\/j.encep.2012.01.014_bib0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(09)61376-3","article-title":"Autism","volume":"375","author":"Levy","year":"2009","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.encep.2012.01.014_bib0800","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1754.2007.00995.x","article-title":"Drug therapy for attention-deficit\/hyperactivity disorder-like symptoms in autistic disorder","volume":"43","author":"Hazell","year":"2007","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"10.1016\/j.encep.2012.01.014_bib0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/104454604773840481","article-title":"A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders","volume":"14","author":"Stigler","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.encep.2012.01.014_bib0130","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","author":"RUPP","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2012.01.014_bib0135","unstructured":"Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of adhd: an open-label study [Internet]. J Atten Disord 2010 [cit\u00e9 2010\u00a0Sep 19] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20686100"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0140","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficit\/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2006.16.611","article-title":"Atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study","volume":"16","author":"Troost","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"10.1016\/j.encep.2012.01.014_bib0150","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder","volume":"50","author":"Gordon","year":"1993","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2012.01.014_bib0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study","volume":"21","author":"Remington","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0165","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10803-005-3305-2","article-title":"Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism","volume":"35","author":"Sugie","year":"2005","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S1461145701002280","article-title":"Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study","volume":"4","author":"Buchsbaum","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0175","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.encep.2012.01.014_bib0180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/cap.2006.16.181","article-title":"The use of selective serotonin reuptake inhibitors in autism and related disorders","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0185","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0190","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80\u00a0cases","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.encep.2012.01.014_bib0200","doi-asserted-by":"crossref","first-page":"I85","DOI":"10.1007\/s007870070022","article-title":"Medication treatment in subjects with autistic spectrum disorders","volume":"9","author":"Buitelaar","year":"2000","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF01487073","article-title":"Open trial effects of beta-blockers on speech and social behaviors in 8\u00a0autistic adults","volume":"17","author":"Ratey","year":"1987","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01058158","article-title":"Brief report: a double-blind study of naltrexone in infantile autism","volume":"24","author":"Leboyer","year":"1994","journal-title":"J Autism Dev Disord"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0215","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00004583-199311000-00024","article-title":"Naltrexone in autistic children: behavioral symptoms and attentional learning","volume":"32","author":"Campbell","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children","volume":"58","author":"Willemsen-Swinkels","year":"1995","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0225","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.encep.2008.01.004","article-title":"Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form","volume":"35","author":"Desjardins","year":"2009","journal-title":"Enc\u00e9phale"},{"issue":"1","key":"10.1016\/j.encep.2012.01.014_bib0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0140-6736(88)91525-5","article-title":"Effects on naltrexone on infantile autism","volume":"26","author":"Leboyer","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mrdd.20031","article-title":"Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis","volume":"10","author":"Symons","year":"2004","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"3","key":"10.1016\/j.encep.2012.01.014_bib0315","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-1781(95)02601-R","article-title":"Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study","volume":"58","author":"Bouvard","year":"1995","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.encep.2012.01.014_bib0240","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0245","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0250","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004714-198712000-00005","article-title":"Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology","volume":"7","author":"Kerbeshian","year":"1987","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0260","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00004583-198726060-00021","article-title":"Lithium responsive manic-like symptoms in two individuals with autism and mental retardation","volume":"26","author":"Steingard","year":"1987","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.encep.2012.01.014_bib0265","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0074-7742(05)72014-6","article-title":"Catatonia in autistic spectrum disorders: a medical treatment algorithm","volume":"72","author":"Fink","year":"2006","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"10.1016\/j.encep.2012.01.014_bib0270","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF02178195","article-title":"The use of buspirone with aggressive behavior","volume":"25","author":"Hillbrand","year":"1995","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.2004.00546.x","article-title":"Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial","volume":"29","author":"Akhondzadeh","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.encep.2012.01.014_bib0280","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0079-6123(08)00435-4","article-title":"Oxytocin and experimental therapeutics in autism spectrum disorders","volume":"170","author":"Bartz","year":"2008","journal-title":"Prog Brain Res"},{"issue":"9","key":"10.1016\/j.encep.2012.01.014_bib0285","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0910249107","article-title":"Promoting social behavior with oxytocin in high-functioning autism spectrum F disorders","volume":"107","author":"Andari","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.encep.2012.01.014_bib0290","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chc.2008.06.010","article-title":"Developing drugs for core social and communication impairment in autism","volume":"17","author":"Posey","year":"2008","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"4","key":"10.1016\/j.encep.2012.01.014_bib0295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.chc.2008.06.004","article-title":"Complementary and alternative medicine treatments for children with autism spectrum disorders","volume":"17","author":"Levy","year":"2008","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.encep.2012.01.014_bib0300","first-page":"CD003495","article-title":"Intravenous secretin for autism spectrum disorder","volume":"3","author":"Williams","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.encep.2012.01.014_bib0305","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2214.2006.00616.x","article-title":"Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems","volume":"32","author":"Garstang","year":"2006","journal-title":"Child Care Health Dev"},{"issue":"2","key":"10.1016\/j.encep.2012.01.014_bib0310","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5664\/jcsm.27443","article-title":"The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome","volume":"5","author":"Wirojanan","year":"2009","journal-title":"J Clin Sleep Med"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700612000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700612000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T20:35:56Z","timestamp":1597264556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700612000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0013700612000152"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2012.01.014","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}